Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-07-30
2010-12-28
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S207000, C544S209000
Reexamination Certificate
active
07858626
ABSTRACT:
Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.
REFERENCES:
patent: 6022307 (2000-02-01), Salvati et al.
patent: 6265411 (2001-07-01), Thomas et al.
patent: 6294532 (2001-09-01), Thomas et al.
patent: 6316603 (2001-11-01), McTigue et al.
patent: 7074789 (2006-07-01), Armistead et al.
patent: 7105530 (2006-09-01), Boloor et al.
patent: 7262203 (2007-08-01), Boloor et al.
patent: 7282504 (2007-10-01), Armistead et al.
patent: 2003/0004174 (2003-01-01), Armistead et al.
patent: 2004/0116388 (2004-06-01), Armistead et al.
patent: 0 002 341 (1978-11-01), None
patent: 0 945 443 (1999-09-01), None
patent: 0 787 742 (2001-12-01), None
patent: 93/11106 (1993-06-01), None
patent: 96/05177 (1996-02-01), None
patent: 97/19065 (1997-05-01), None
patent: 97/22596 (1997-06-01), None
patent: 97/30035 (1997-08-01), None
patent: 97/32856 (1997-09-01), None
patent: 97/34786 (1997-09-01), None
patent: 98/18782 (1998-05-01), None
patent: 98/54093 (1998-12-01), None
patent: 99/16755 (1999-04-01), None
patent: 99/60630 (1999-11-01), None
patent: 99/62890 (1999-12-01), None
patent: 00/02871 (2000-01-01), None
patent: 00/12089 (2000-03-01), None
patent: 00/12485 (2000-03-01), None
patent: 00/14105 (2000-03-01), None
patent: 00/21955 (2000-04-01), None
patent: 00/39101 (2000-07-01), None
patent: 00/43373 (2000-07-01), None
patent: 00/47212 (2000-08-01), None
patent: 00/52470 (2000-09-01), None
patent: 00/53595 (2000-09-01), None
patent: 00/53605 (2000-09-01), None
patent: 00/59892 (2000-10-01), None
patent: 00/63204 (2000-10-01), None
patent: 00/73264 (2000-12-01), None
patent: 01/00213 (2001-01-01), None
patent: 01/09134 (2001-02-01), None
patent: 01/14375 (2001-03-01), None
patent: 01/17995 (2001-03-01), None
patent: 01/25220 (2001-04-01), None
patent: 01/40218 (2001-06-01), None
patent: 01/47921 (2001-07-01), None
patent: 01/60816 (2001-08-01), None
patent: 01/64654 (2001-09-01), None
patent: 01/64655 (2001-09-01), None
patent: 01/64656 (2001-09-01), None
patent: 01/74296 (2001-10-01), None
patent: 02/22601 (2002-03-01), None
patent: 02/50045 (2002-06-01), None
Arasteh et al., “The Role of Vascular Endothelial Growth Factor (VEGF) in AIDS-Related Kaposi's Sarcoma,”The Oncologist, 2000, vol. 5 (Supp. 1), pp. 28-31.
Arutyunyan et al., “Certain Peculiarities in the Reaction of Uracils with Phosphoric Acid Amides,”N.D. Zelinskii Institute of Organic Chemistry, Academy of Sciences of the USSR, pp. 848-853.
Banker et al., “Modern Pharaceutices, 3 ed.,” Marcel Dekker, New York, 1996, pp. 451 and 596.
Carter, “Clinical Strategy for the Development of Angiogenesis Inhibitors,”The Oncologist, vol. 5 (Supp. 1), 2000, pp. 51-54.
Cecil Textbook of Medicine, eds. Bennet and Plum, 20thed., 1996, vol. 1, pp. 1004-1010.
Connell et al., “Patent Focus on Cancer Chemotherapies. II Angiogenesis Agents: Apr. 2000-Sep. 2000,”Exp. Opinion Ther. Patients, 2001, vol. 11, No. 1, pp. 77-114.
Ellis et al., “Vascular Endothelial Growth Factor in Human Colon Cancer: Biology and Therapeutic Implications,”The Oncologist, 2000, vol. 5 (Supp. 1), pp. 11-15.
Gasparini, “Prognostic Value of Vascular Endothelial Growth Factor in Breast Cancer,”The Oncologist, 2000, vol. 5 (Supp. 1), pp. 37-44.
Ghosh, “2,4-Bis(Arylamino)-6-Methyl Pyrimidines as Antimicrobial Agents,”J. Indian Chem. Soc., vol. LVIII, May 1981, pp. 512-513.
Ghosh et al., “2,4 BIS(p-Chloroanilino)-Pyrimidine, an Uncoupler of Oxidative Phosphorylation,”FEBS Letters, vol. 4, No. 3, Aug. 1969, pp. 157-159.
Harris, “von Hippel-Lindau Syndrome: Target for Anti-Vascular Endothelial Growth Factor (VEGF) Receptor Therapy,”The Oncologist, 2000, vol. 5 (Supp. 1), pp. 32-36.
Kerbel, “A Cancer Therapy Resistant to Resistance,”Nature, Nov. 1997, vol. 390, pp. 335-336.
Kerdawy et al., “Synthesis of Certain Esters of Pteroyl Glutamic Acid Analogues Structurally Related to Antimetabolite Anticancer Compounds,”J. Pharm. Sci. U.A.R., 1968, vol. 9, pp. 1-6.
Klement et al., “Continuous Low-Dose Therapy with Vinblastine and VEGF Receptor-2 Antibody Induces Sustained Tumor & Regression without Over Toxicity,”Journal of Clinical Investigation, Apr. 2000, vol. 105, No. 8, pp. 15-24.
McMahon, “VEGF Receptor Signaling in Tumor Angiogenesis,”The Oncologist, 2000, vol. 5 (Supp. 1), pp. 3-10.
Pinedo et al., “Translational Research: The Role of VEGF in Tumor Angiogenesis,”The Oncologist, 2000, vol. 5 (Supp. 1), pp. 1-2.
Rose, “Antiangiogenic Strategies and Agents in Clincial Trials,”The Oncologist, 2000, vol. 5 (Supp. 1), pp. 20-27.
Russian Article #1, pp. 7-18, 1983.
Russian Article #2, pp. 1304-1307.
Sennlaub et al.,The Journal of Clinical Investigation, 2001, vol. 107, No. 6, pp. 717-725.
Shawyer et al., “Receptor Tyrosine Kinases as Targets for Inhibition of Angiogenesis,”DDT, vol. 2, No. 2, Feb. 1997, pp. 50-63.
Vajkoczy et al., “Measuring VEGF-Flk-1 Activity and Consequences of VEGF-Flk-1 Targeting In Vivo Using Intravital Microscopy: Clinical Applications,”The Oncologist, 2000, vol. 5 (Supp. 1), pp. 16-19.
Verheul et al., “Targeting Vascular Endothelial Growth Factor Blockade: Ascites and Pleural Effusion Formation,”The Oncologist, 2000, vol. 5 (Supp. 1), pp. 45-50.
Vippagunta et al.,Advanced Drug Delivery Reviews, 2001, vol. 48, pp. 3-26.
West, “Solid State Chemistry and Its Applications,” Wiley, New York, 1988, pp. 358 and 365.
Wolft, “Burger's Medicinal Chemistry, 5 ed., Part 1,” John Wiley & Sons, 1995, pp. 975-977.
Toledo et al., “The Structure-Based Design of ATP-Site Directed Protein Kinase Inhibitors,”Current Medicinal Chemistry, 1999, vol. 6, No. 9, pp. 775-805.
Boloor Amogh
Cheung Mui
Davis-Ward Ronda Gayle
Harris Philip Anthony
Hinkle Kevin
Balasubramanian Venkataraman
GlaxoSmithKline LLC
Strickland J. Michael
LandOfFree
Pyrimidineamines as angiogenesis modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidineamines as angiogenesis modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidineamines as angiogenesis modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4228180